Kooby David A, Jarnagin William R
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.
Cancer Invest. 2004;22(2):283-303. doi: 10.1081/cnv-120030217.
Over the past twenty-five years, hepatic resection has evolved from a high risk, resource-intensive procedure with limited application to a safe and commonly performed operation with broad indications. This period has seen dramatic improvements in perioperative outcome, including reductions in mortality, blood loss, transfusion rates, and hospital stay. These improved perioperative results are largely responsible for the emergence of hepatic resection as a viable and effective treatment option for selected patients with 1 degree and 2 degrees hepatobiliary malignancy. Continued advances in imaging technology, along with a heightened awareness of the clinical and tumor-related variables that dictate outcome, have allowed better preoperative assessment of disease extent and improved patient selection. Advances in other areas, such as minimally invasive and ablative techniques, have increased the treatment options and have had some impact on the approach to patients with malignant hepatobiliary disease; however, resection remains the most effective therapy. Although the long term results after resection are better than with other modalities, recurrence rates remain high, and further improvements in survival will require more effective systemic agents. As better adjuvant and neo-adjuvant therapies emerge, the results of resection are likely to improve and the indications for its application perhaps will extend to patients currently considered to have unresectable disease.
在过去的二十五年里,肝切除术已从一种风险高、资源消耗大、应用有限的手术,演变为一种安全且普遍施行、适应证广泛的手术。这一时期围手术期的结果有了显著改善,包括死亡率、失血量、输血率和住院时间的降低。这些围手术期结果的改善在很大程度上促使肝切除术成为选定的I期和II期肝胆恶性肿瘤患者可行且有效的治疗选择。成像技术的不断进步,以及对决定预后的临床和肿瘤相关变量的更高认识,使得对疾病范围的术前评估更好,患者选择也得到改善。其他领域的进展,如微创和消融技术,增加了治疗选择,并对肝胆恶性疾病患者的治疗方法产生了一些影响;然而,切除术仍然是最有效的治疗方法。尽管切除术后的长期结果优于其他治疗方式,但复发率仍然很高,生存的进一步改善将需要更有效的全身治疗药物。随着更好的辅助和新辅助治疗方法的出现,切除的结果可能会改善,其应用适应证或许将扩展到目前被认为不可切除疾病的患者。